Taltz patent expiration date?

Taltz (ixekizumab) – Main Patent Expiration

Bottom line:
The primary patents that protect the active ingredient of Taltz expire at the end of 2029 (December 31 2029). Some secondary patents (formulation, delivery, and method‑of‑treatment claims) last a few years longer, up to the end of 2032.

What does this mean for patients?

• Generics: The first generic versions of ixekizumab are not expected to reach the market until after the 2029 expiration, assuming all patents are enforced.
• Patent litigation: Eli Lilly may pursue secondary patents that could delay entry for a few more years.
• Pricing: The drug remains under the brand name Taltz with the associated pricing structure until generics enter the market post‑2029.

How to verify or track changes

• USPTO Patent Full-Text and Image Database (PatFT) – search by “ixekizumab” or “Taltz” to see all active patents and their expiration dates.
• FDA Orange Book – lists exclusivity periods for approved biologics; for Taltz the exclusivity ends 2029 (matching the main patent).
• Eli Lilly press releases – often announce patent expirations or extensions.

Disclaimer

This information reflects the publicly available patent data as of 2026‑08‑01. Patent expirations can be subject to extensions (e.g., Patent and Trademark Office (PTO) term extensions, “patent term adjustments,” or legal challenges), so the actual commercial availability of generics may shift. For the most up‑to‑date, legally binding information, consult the USPTO database or a qualified patent attorney.